The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Corvidia Therapeutics Inc. (Corvidia) located in Waltham, MA and incorporated under the laws of Delaware.
Document
Prospective Grant of Exclusive Patent License: Development and Commercialization of Peptides Promoting Lipid Efflux for the Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome
The National Heart, Lung, and Blood Institute (NHLBI), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contem...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 16405
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Development and Commercialization of Peptides Promoting Lipid Efflux for the Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome,” thefederalregister.org (April 4, 2017), https://thefederalregister.org/documents/2017-06546/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-peptides-promoting-lipid-efflux-for-t.